Therefore, KRAS mutation is positively correlated with the curative effect of ICIs in cancer patients, but KRAS-G12C mutation is correlated with the shorter tumor recurrence time in early NSCLC patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.